Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.
Patients with pulmonary arterial hypertension who achieve a six-minute walk distance of 380-440 m may have improved prognosis. Using the randomized controlled trial of macitentan in pulmonary arterial hypertension (SERAPHIN), the association between six-minute walk distance and long-term outcomes was explored.
Patients with six-minute walk distance data at Month 6 were dichotomized as above or below the median six-minute walk distance (400 m) and assessed for future risk of pulmonary arterial hypertension-related death or hospitalization and all-cause death. Additionally, six-minute walk distance values at baseline, Month 6 and the change from baseline to Month 6 were categorized by quartiles. All associations were analyzed by the Kaplan-Meier method using a log-rank test and Cox regression models.
Patients with a six-minute walk distance >400 m vs. ≤400 m at Month 6 have a reduced risk of pulmonary arterial hypertension-related death or hospitalization (hazard ratio 0.48; 95% confidence interval 0.33-0.69). The risk was also lower for patients with higher quartiles of six-minute walk distance at baseline or Month 6 (baseline: hazard ratio [Q4 (>430 m) vs. Q1 (≤300 m)] 0.23; 95% confidence interval 0.15-0.36; Month 6: hazard ratio [Q4 (>455 m) vs. Q1 (≤348 m)] 0.33; 95% confidence interval 0.19-0.55). In contrast, six-minute walk distance changes at Month 6 were not associated with the risk of pulmonary arterial hypertension-related death or hospitalization (p = 0.477). These findings were consistent when adjusted for known confounders. Similar results were observed for the risk of all-cause death up to end of study.
Patients with pulmonary arterial hypertension walking >400 m had better long-term prognosis. Although changes in six-minute walk distance were not associated with long-term outcomes, assessing absolute six-minute walk distance values remains important in the clinical management of patients with pulmonary arterial hypertension.
六分钟步行距离达到 380-440 米的肺动脉高压患者可能预后改善。本研究利用肺动脉高压随机对照试验(SERAPHIN)探索了六分钟步行距离与长期结局的关系。
对六分钟步行距离数据在 6 个月时处于中位数(400 米)以上或以下的患者进行二分法,并评估肺动脉高压相关死亡或住院和全因死亡的未来风险。此外,还根据四分位数将六分钟步行距离的基线、6 个月时和从基线到 6 个月的变化进行分类。所有关联均通过 Kaplan-Meier 方法使用对数秩检验和 Cox 回归模型进行分析。
六分钟步行距离>400 米与≤400 米的患者在 6 个月时肺动脉高压相关死亡或住院风险降低(风险比 0.48;95%置信区间 0.33-0.69)。基线或 6 个月时六分钟步行距离处于较高四分位数的患者风险也较低(基线:风险比 [Q4(>430 米)比 Q1(≤300 米)] 0.23;95%置信区间 0.15-0.36;6 个月:风险比 [Q4(>455 米)比 Q1(≤348 米)] 0.33;95%置信区间 0.19-0.55)。相反,6 个月时的六分钟步行距离变化与肺动脉高压相关死亡或住院的风险无关(p=0.477)。在调整了已知混杂因素后,这些发现仍然一致。直到研究结束,全因死亡风险也观察到了类似的结果。
六分钟步行距离>400 米的肺动脉高压患者预后更好。虽然六分钟步行距离的变化与长期结局无关,但评估绝对六分钟步行距离值在肺动脉高压患者的临床管理中仍然很重要。